- Home
- ASPI vs CGEM Comparison
ASPI vs CGEM Comparison
Compare ASPI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- CGEM
- Stock Information
- Founded
- ASPI 2021
- CGEM 2016
- Country
- ASPI United States
- CGEM United States
- Employees
- ASPI N/A
- CGEM N/A
- Industry
- ASPI Major Chemicals
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- CGEM Health Care
- Exchange
- ASPI Nasdaq
- CGEM Nasdaq
- Market Cap
- ASPI 653.4M
- CGEM 530.0M
- IPO Year
- ASPI 2022
- CGEM 2021
- Fundamental
- Price
- ASPI $6.84
- CGEM $7.70
- Analyst Decision
- ASPI Strong Buy
- CGEM Strong Buy
- Analyst Count
- ASPI 2
- CGEM 5
- Target Price
- ASPI $7.75
- CGEM $30.00
- AVG Volume (30 Days)
- ASPI 3.6M
- CGEM 354.7K
- Earning Date
- ASPI 08-18-2025
- CGEM 08-07-2025
- Dividend Yield
- ASPI N/A
- CGEM N/A
- EPS Growth
- ASPI N/A
- CGEM N/A
- EPS
- ASPI N/A
- CGEM N/A
- Revenue
- ASPI $4,405,477.00
- CGEM N/A
- Revenue This Year
- ASPI $512.64
- CGEM N/A
- Revenue Next Year
- ASPI $181.15
- CGEM N/A
- P/E Ratio
- ASPI N/A
- CGEM N/A
- Revenue Growth
- ASPI 245.97
- CGEM N/A
- 52 Week Low
- ASPI $1.86
- CGEM $6.85
- 52 Week High
- ASPI $10.08
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- ASPI 45.07
- CGEM 40.12
- Support Level
- ASPI $6.59
- CGEM $7.29
- Resistance Level
- ASPI $7.24
- CGEM $8.05
- Average True Range (ATR)
- ASPI 0.53
- CGEM 0.42
- MACD
- ASPI -0.12
- CGEM -0.07
- Stochastic Oscillator
- ASPI 25.00
- CGEM 17.48
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.